All Columns articles
View all stories with this category.
-
OpinionReturning to the moon
It’s been a while, but space agencies are starting to plan their trips back to our satellite, with the goal of building semi-permanent bases
-
Opinion
Regulators must follow their heads, not their hearts
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
-
Opinion
Lessons from Lieber
The prosecution of Charles Lieber has had a chilling effect on US researchers, leaving them uncertain about collaboration with overseas programmes
-
Opinion
Battery materials going up in smoke
We cannot afford to simply throw away, rather than recycle, these valuable resources
-
Opinion
Will a court overturn abortion drug’s approval?
Tangle between regulation and politics makes uncomfortable viewing from industry
-
-
Opinion
Nursing success – what next for UK science?
Policy prescriptions for research need cross-party support
-
Opinion
Meeting the tigers of the lab
Practical teaching strikes a balance between removing hazards and learning to respect them
-
Opinion
Holding the keys to a powerful future
Competition to build battery supply chains means supercharging support to attract investment
-
Opinion
Nuclear wasted
Atomic energy has the potential to reduce our carbon footprint, but the problem of waste is devilishly complex
-
-
Opinion
N-heterocyclic carbenes are more than passive spectators
The practical importance of N-heterocyclic carbenes continues to grow
-
Opinion
Turning negative results into positives
Publishing unsuccessful experiments is more important than ever as we try to train machines in chemistry
-
Careers
More guidance makes job and university applications fairer
A question-based format helps candidates prioritise what to tell recruiters
-
Opinion
A decade on Crispr is already poised to deliver on its promise
Gene editing could transform healthcare but no disease should be forgotten
-
Opinion
How long until papers list an AI as an author?
Artificial intelligence is superior to humans at numerous tasks, but it is still vulnerable to human biases
-
Opinion
Setting drug development speed records
The pandemic treatment sprint was spectacular, but hard to match under less unusual circumstances
-
-
Opinion
Will we always keep naming things after people?
Choosing a name deserves careful consideration
-
Opinion
Embracing oddities
When new chemistry looks like alchemy or witchcraft, it’s worth taking notice
